David Peereboom
Case Comprehensive Cancer Center, Cleveland Clinic Taussig Cancer Institute · Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center · Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name David Peereboom as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:26 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07003542 · A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 GliomasCase Comprehensive Cancer Center · recruiting · Glioblastoma, Brain Tumor · principal investigator
- Ph2NCT05607407 · Methimazole in Patients With Progressive GlioblastomaCase Comprehensive Cancer Center · suspended · Glioblastoma, Glioma · principal investigator
- Ph2NCT04051606 · Regorafenib in Bevacizumab Refractory Recurrent GlioblastomaCase Comprehensive Cancer Center · completed · Recurrent Glioblastoma · principal investigator
- Ph2NCT04013672 · Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First RecurrenceDavid Peereboom · completed · Recurrent Glioblastoma · principal investigator
- Ph1NCT03535350 · Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed GlioblastomaCase Comprehensive Cancer Center · completed · Glioblastoma · principal investigator
- Ph1NCT03514069 · Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and GlioblastomaCase Comprehensive Cancer Center · completed · Glioma, Glioblastoma · principal investigator
- Ph2NCT03452579 · Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBMDavid Peereboom · active not recruiting · Glioblastoma · principal investigator
- Ph1NCT02669173 · Capecitabine + Bevacizumab in Patients With Recurrent GlioblastomaCase Comprehensive Cancer Center · completed · Glioblastoma · principal investigator
- Ph2NCT01894061 · NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent GlioblastomaCase Comprehensive Cancer Center · completed · Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma · principal investigator
- Ph2NCT01122901 · Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive GlioblastomaNational Cancer Institute (NCI) · terminated · Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma · principal investigator
- Ph2NCT01095094 · Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade GliomaCase Comprehensive Cancer Center · terminated · Brain Tumor, Anaplastic Astrocytoma, Anaplastic Ependymoma · principal investigator
- Ph2NCT00445588 · Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma MultiformeNational Cancer Institute (NCI) · completed · Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma · principal investigator
- Ph1/Ph2NCT00045708 · A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade GliomasNational Cancer Institute (NCI) · completed · Adult Anaplastic Astrocytoma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:26 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Adult Brain Tumor Consortium (ABTC)U01CA137443 · NCI · JOHNS HOPKINS UNIVERSITY · PI STUART A GROSSMAN, MICHAEL D PRADOS · fiscal years 2009 to 2013Named on NCT01122901
- NABTT-Consortium Therapeutic Studies of CNS MalignanciesU01CA062475 · NCI · JOHNS HOPKINS UNIVERSITY · PI STUART A GROSSMAN · fiscal years 1994 to 2008Named on NCT00445588, NCT00045708
Most cited trial papers
Clinical-trial papers with this author name in glioma, ranked by citations from NIH iCite, fetched 2026-11-12 12:26 UTC. The ranking covers the 200 most relevant of 31 PubMed records, and a shared surname and initials can bring in a namesake. All 31 on PubMed
- Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.Nat Med · 2023275 citationsRCR 24.2
- A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma.Clin Cancer Res · 2019243 citationsRCR 8.9
- Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.J Neurooncol · 2010155 citationsRCR 3.8
- Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma.J Clin Oncol · 2023148 citationsRCR 13.7
- Propylthiouracil-induced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: a phase I/II study.Anticancer Res · 2003110 citationsRCR 2.4
- 108 citationsRCR 3.0
- Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells.JCI Insight · 2019103 citationsRCR 3.5
- A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma.Neuro Oncol · 201093 citationsRCR 2.0
- NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.Neuro Oncol · 201382 citationsRCR 2.4
- 55 citationsRCR 1.6